Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 160-164

  Parashar, Bhupesh ^a   Edwards, Alison ^a   Mehta, Rajeev ^b   Pasmantier, Mark ^a   Wernicke, A Gabriella ^a   Sabbas, Albert ^a   Kerestez, Roger S ^c   Nori, Dattatreyudu ^a   Chao, K S Clifford ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Age; Chemotherapy; Incidence; Pneumonitis; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ASSESSMENT; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RADIATION DOSE; RADIATION PNEUMONIA; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RADIATION PNEUMONITIS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 79955945185     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d6b40f     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452-462. (Pubitemid 40994510)
3. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945. (Pubitemid 20332333)
4. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360-367.
5. Sause WT, Scott C, Taylor S, et al; Radiation Therapy Oncology Group (RTOG) 88-08; Eastern Cooperative Oncology Group (ECOG) 4588. Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198-205.
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699. (Pubitemid 29415225)
7. Curran W, Scott C, Langer C, et al. Long term beneflt is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC:RTOG 9410 [abstract]. Proc Am Soc Clin Oncol. 2003;61.
8. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-5917.
9. Goto K, Nishiwaki Y, Takada M, et al; the Japan Clinical Oncology Group (JCOG) Study. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC) [abstract]. Proc Am Soc Clin Oncol. 1999;18:468.
10. Murray N, Coy P, Pater JL, et al; The National Cancer Institute of Canada Clinical Trials Group. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1993;11:336-344. (Pubitemid 23046826)
11. Hope AJ, Lindsay PE, El Naqa I, et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys. 2006;65:112-124.
12. Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001;49:649-655. (Pubitemid 32114101)
13. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67:275-283. (Pubitemid 36831080)
14. Claude L, Pérol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175-181. (Pubitemid 38521186)
15. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323-329. (Pubitemid 29408545)
16. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650-659.
17. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1-9. (Pubitemid 28435589)
18. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724-735. (Pubitemid 36170012)
19. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol. 1996;14:1055-1064. (Pubitemid 26105509)
20. Roach M III, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995;13:2606-2612.
21. Das SK, Chen S, Deasy JO, et al. Combining multiple models to generate consensus: application to radiation-induced pneumonitis prediction. Med Phys. 2008;35:5098-5109.
22. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer: a systematic review. Radiother Oncol. 2004;71:127-138. (Pubitemid 38521180)
23. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650-659.
24. Chikamori K, Kishino D, Takigawa N, et al; Okayama Lung Cancer Study Group. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer. 2008;65:74-79.
25. Hanna N, Neubauer M, Yiannoutsos C, et al; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer. J Clin Oncol. 2008;26:5755-5760.
26. Seung SK, Ross HJ. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:802-809.
27. Zhao YH, Li ZP, Chen XM, et al. Correlation study of physical and biologic parameters to acute radiation pneumonitis [in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008;39:796-800.
28. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82:842-850. (Pubitemid 28104162)
29. Yamano M, Ogino H, Shibamoto Y, et al. Relationship between radiation pneumonitis and prognosis in patients with primary lung cancer treated by radiotherapy. Kurume Med J. 2007;54:57-63. (Pubitemid 351775686)